Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan-Reference-Cited by-同舟云学术

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

Published:2022-08 Issue:8 Volume:17 Page:1002-1013
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hibino Makoto,Uryu Kiyoaki,Takeda Takayuki,Kunimatsu Yusuke,Shiotsu Shinsuke,Uchino Junji,Hirai Soichi,Yamada Tadaaki,Okada Asuka,Hasegawa Yoshikazu,Hiranuma Osamu,Chihara Yusuke,Kamada Riko,Tobe Shunichi,Maeda Kazunari,Horiuchi Shigeto,Kondo Tetsuri,Takayama Koichi

Funder

Abbott Laboratories

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Economic consequences of the COVID-19 outbreak: the need for epidemic preparedness;Pak;Front Public Health,2020

2. COVID-19—recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines;Iqbal Yatoo;Hum Vaccin Immunother,2020

3. COVID-19 and cancer: current challenges and perspectives;Bakouny;Cancer Cell,2020

4. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium;Grivas;Ann Oncol,2021

5. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study;Kuderer;Lancet,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors and SARS-CoV2 infection;International Immunopharmacology;2024-08

2. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer;Vaccines;2024-06-26

3. Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer;Cancer Medicine;2024-04

4. Serological response and immune‐related adverse events following COVID‐19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis;Reviews in Medical Virology;2023-11-28

5. Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China;BMC Cancer;2023-11-06